---
figid: PMC11853781__cimb-47-00126-g003
figtitle: Luteolin multi-pathway treatment of IBD
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC11853781
filename: cimb-47-00126-g003.jpg
figlink: /pmc/articles/PMC11853781/figure/F3/
number: F3
caption: 'Luteolin multi-pathway treatment of IBD. (Luteolin exerts its therapeutic
  effects through four main pathways: (A) Regulation of immune cell differentiation—promoting
  Treg cell generation while inhibiting inflammatory Th1/Th17 cells and macrophage
  activation; (B) reduction in inflammatory response and ROS—decreasing inflammatory
  mediators (iNOS, TNF-α, IL-6) and activating antioxidant pathways (Nrf2/HO-1); (C)
  repair of intestinal mucosal barrier—enhancing tight junction proteins (ZO-1, Occludin)
  expression and promoting intestinal epithelial restoration through the SHP-1/STAT3
  pathway); (D) regulation of gut microbiota—increasing beneficial bacteria (Lactobacillus,
  Bacteroides) and modulating microbiota composition'
papertitle: 'Luteolin in Inflammatory Bowel Disease and Colorectal Cancer: A Disease
  Continuum Perspective'
reftext: Fang Liu, et al. Curr Issues Mol Biol. 2025 Feb;47(2).
year: '2025'
doi: 10.3390/cimb47020126
journal_title: Current Issues in Molecular Biology
journal_nlm_ta: Curr Issues Mol Biol
publisher_name: Multidisciplinary Digital Publishing Institute  (MDPI)
keywords: luteolin | inflammatory bowel disease | colorectal cancer | ulcerative colitis
  | natural products
automl_pathway: 0.9583563
figid_alias: PMC11853781__F3
figtype: Figure
redirect_from: /figures/PMC11853781__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11853781__cimb-47-00126-g003.html
  '@type': Dataset
  description: 'Luteolin multi-pathway treatment of IBD. (Luteolin exerts its therapeutic
    effects through four main pathways: (A) Regulation of immune cell differentiation—promoting
    Treg cell generation while inhibiting inflammatory Th1/Th17 cells and macrophage
    activation; (B) reduction in inflammatory response and ROS—decreasing inflammatory
    mediators (iNOS, TNF-α, IL-6) and activating antioxidant pathways (Nrf2/HO-1);
    (C) repair of intestinal mucosal barrier—enhancing tight junction proteins (ZO-1,
    Occludin) expression and promoting intestinal epithelial restoration through the
    SHP-1/STAT3 pathway); (D) regulation of gut microbiota—increasing beneficial bacteria
    (Lactobacillus, Bacteroides) and modulating microbiota composition'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - stat3
  - il10
  - il6
  - tnfb
  - cxcl8a
  - stat1b
  - stat4
  - tnfa
  - stat1a
  - pask
  - cldn10e
  - keap1a
  - nfe2l2a
  - cat
  - STAT3
  - IL10
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - IL6
  - TNF
  - CXCL8
  - SOAT1
  - STAT1
  - STAT2
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - TLR4
  - IL12A
  - IL12B
  - IL18
  - KEAP1
  - GABPA
  - NFE2L2
  - SOD1
  - SOD2
  - SOD3
  - CAT
  - CRAT
  - GLYAT
  - IL17A
  - IL37
  - IL23A
  - Luteolin
  - ROS
  - MDA
  - CAT
  - Nucleus
  - TNF-a
  - SCFA
---
